Trial Profile
A Phase I/II Clinical Trial of Nivolumab and Plinabulin for Patients With Advanced Stage Non-small Cell Lung Cancer That Have Progressed Through First Line Platinum Doublet Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Plinabulin (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 27 Feb 2019 Status changed from recruiting to discontinued.
- 09 Nov 2018 Planned primary completion date changed from 31 Mar 2018 to 31 Mar 2019.
- 09 Nov 2017 According to a BeyondSpring Pharmaceuticals media release, phase 1 data on the safety and mechanism of action of this regimen are expected in the first quarter of 2018, Enrollement in the phase 2 portion has recently commenced.